Zhengye Biotechnology Holding (ZYBT) Debt to Equity (2023 - 2025)
Zhengye Biotechnology Holding has reported Debt to Equity over the past 3 years, most recently at $0.24 for Q4 2025.
- Quarterly Debt to Equity rose 7.26% to $0.24 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $0.24 through Dec 2025, up 7.26% year-over-year, with the annual reading at $0.23 for FY2025, 15.92% down from the prior year.
- Debt to Equity was $0.24 for Q4 2025 at Zhengye Biotechnology Holding, up from $0.01 in the prior quarter.
- Over five years, Debt to Equity peaked at $0.24 in Q4 2025 and troughed at $0.01 in Q2 2025.
- The 3-year median for Debt to Equity is $0.23 (2023), against an average of $0.18.
- Year-over-year, Debt to Equity fell 4.97% in 2024 and then rose 7.26% in 2025.
- A 3-year view of Debt to Equity shows it stood at $0.24 in 2023, then decreased by 4.97% to $0.22 in 2024, then grew by 7.26% to $0.24 in 2025.
- Per Business Quant, the three most recent readings for ZYBT's Debt to Equity are $0.24 (Q4 2025), $0.01 (Q2 2025), and $0.22 (Q4 2024).